Immunovant AI Stock Analysis
Want to see IMVT full AI Analyst Report?
Immunovant (IMVT) AI Stock Analysis
Immunovant
(NASDAQ:IMVT)
The score is held back primarily by weak financial performance (very large losses and heavy cash burn with minimal revenue), partially offset by a debt-free balance sheet. The earnings call provided a meaningful boost due to strong launch/pipeline momentum and positive sentiment, while technical signals are mixed and valuation remains constrained by ongoing unprofitability and no dividend.
Immunovant (IMVT) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $6.73B
- Dividend Yield
- ―
- Average Volume (3M)
- 1.42M
- Price to Earnings (P/E)
- -12.7
- Beta (1Y)
- 1.24
- Revenue Growth
- ―
- EPS Growth
- 9.82%
- Country
- US
- Employees
- 315
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Immunovant Business Overview & Revenue Model
Company Description
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fu...
Immunovant Earnings Call Summary
The call was strongly positive, driven by the successful LISRAYA launch, robust early commercial demand, positive 1402 RA maintenance data, favorable NIU results, and compelling mosliciguat PH-ILD data. The company also has substantial cash, active share repurchases, and a broad 2027 pipeline. The main negative items were the failed CLE study, the likely discontinuation of Sjögren's development, ongoing uncertainty around the 1402 regulatory path, a potential modest near-term inventory headwind, and the quarterly net loss. Highlights significantly outweighed lowlights.
Q2-2027 Updates
Positive Updates
Negative Updates
Company Guidance
For LISRAYA, management expects “a modest headwind” from inventory dynamics in the December quarter and expects inventory and stocking to be “completely irrelevant as we round the corner into next year”; for IMVT-1402, it expects to update trial plans “probably later this year or early next year” after FDA discussions. In 2027, Roivant expects to file the sNDA for NIU, report top-line data for 1402 in Graves’ and data in MG, and pursue “multiple program indication expansion,” while for mosliciguat it expects updates “in the coming months” on initiation of other trials, with a “pretty broad program” under consideration across PAH, IPF, PPF, and other forms of pulmonary hypertension, although it cannot commit to specific indications or whether they will be phase IIs or phase IIIs. It also expects to provide an update “relatively soon” on Graves’ timing and enrollment.
Immunovant Financial Statement Overview
Summary
Overall financials are weak: minimal TTM revenue (~$7.1M) with no growth, extremely large operating losses (TTM EBIT about -$531M) and deep net losses (TTM net income about -$509M), alongside heavy ongoing cash burn (TTM operating cash flow and free cash flow about -$395M). The key offset is a relatively strong balance sheet with no debt and still-meaningful equity (~$657M), but continued losses and cash outflows remain the dominant risk.
Income Statement
12Very NegativeBalance Sheet
63PositiveCash Flow
18Very Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.09M | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 6.99M | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -509.88M | -504.98M | -412.57M | -258.54M | -198.28M | -156.69M |
| Net Income | -508.96M | -505.61M | -413.84M | -259.34M | -210.96M | -156.73M |
Balance Sheet | ||||||
| Total Assets | 760.97M | 957.01M | 776.22M | 666.71M | 405.84M | 515.56M |
| Cash, Cash Equivalents and Short-Term Investments | 722.27M | 902.11M | 713.97M | 635.37M | 376.53M | 493.82M |
| Total Debt | 0 | 72.00K | 98.00K | 138.00K | 1.22M | 2.36M |
| Total Liabilities | 104.02M | 104.42M | 68.78M | 48.95M | 43.34M | 45.74M |
| Stockholders Equity | 656.95M | 852.59M | 707.45M | 617.76M | 362.49M | 469.82M |
Cash Flow | ||||||
| Free Cash Flow | -395.01M | -407.32M | -376.63M | -214.59M | -188.39M | -106.37M |
| Operating Cash Flow | -395.00M | -407.31M | -375.87M | -214.23M | -188.19M | -106.11M |
| Investing Cash Flow | -8,000 | -8,000 | -759.00K | -360.00K | -197.00K | -254.00K |
| Financing Cash Flow | 596.22M | 595.76M | 454.49M | 472.43M | 70.89M | 200.13M |
Immunovant Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMVT, the sentiment is Positive. The current price of 32.52 is above the 20-day moving average (MA) of 31.29, above the 50-day MA of 32.28, and above the 200-day MA of 32.46, indicating a bullish trend. The MACD of 0.76 indicates Negative momentum. The RSI at 54.18 is Neutral, neither overbought nor oversold. The STOCH value of 53.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IMVT.
Immunovant Risk Analysis
Immunovant disclosed 77 risk factors in its most recent earnings report. Immunovant reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksImmunovant Peers Comparison
Overall Rating
AUPH84Outperform
PTGX72Outperform
TGTX72Outperform
KYMR60Neutral
VRDN55Neutral
IMVT53Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 84Outperform | $2.00B | 6.28 | 51.92% | ― | 21.04% | 312.89% | |
| 72Outperform | $8.09B | 24.04 | 42.83% | ― | 163.69% | 574.89% | |
| 72Outperform | $9.81B | 87.10 | 17.62% | ― | 68.78% | -75.71% | |
| 60Neutral | $10.19B | -32.89 | -22.39% | ― | 133.77% | -0.64% | |
| 55Neutral | $3.57B | -8.12 | -69.76% | ― | -62.83% | -18.22% | |
| 53Neutral | $6.73B | -12.70 | -63.01% | ― | ― | 9.82% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IMVT | Immunovant, Inc. | 32.52 | 9.93 | 43.96% | |
| TGTX | TG Therapeutics | 64.88 | 32.93 | 103.07% | |
| VRDN | Viridian Therapeutics, Inc. | 31.44 | 1.10 | 3.63% | |
| AUPH | Aurinia Pharmaceuticals | 14.89 | -0.79 | -5.04% | |
| PTGX | Protagonist Therapeutics Inc | 124.02 | 38.62 | 45.22% | |
| KYMR | Kymera Therapeutics, Inc. | 119.39 | 53.35 | 80.78% |
Immunovant Corporate Events
Immunovant Shareholders Back Board, Auditor and Executive Pay
PositiveOn September 2, 2026, Immunovant, Inc. held its 2026 Annual Meeting of Stockholders, with approximately 96% of eligible common and Series A preferred shares represented, reflecting strong shareholder engagement. At the meeting, stockholders elected J...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 10, 2026
